-
公开(公告)号：US20150191466A1
公开(公告)日：2015-07-09
申请号：US14628876
申请日：2015-02-23
申请人： Genzyme Corporation
发明人： John L. KANE, JR. , Gloria MATTHEWS , Markus METZ , Michael KOTHE , Jinyu LIU , Andrew SCHOLTE
IPC分类号： C07D471/04 , C07D401/14 , C07D471/08 , C07D403/04 , C07D519/00 , C07D471/10 , C07D405/14 , C07D401/12 , C07D413/14
CPC分类号： A61K31/551 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D519/00 , C07F9/5022 , C07F9/6506 , C07F9/65583 , C07F9/6561
摘要： Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
摘要翻译： 原肌球蛋白相关激酶抑制剂（Trk抑制剂）是用于治疗疾病的小分子化合物。 Trk抑制剂可用作药剂和药物组合物。 Trk抑制剂可用于治疗炎性疾病，自身免疫性疾病，骨代谢缺陷和/或癌症，并且特别可用于治疗骨关节炎（OA），疼痛和与OA相关的疼痛。 Trk抑制剂也可用于抑制原肌球蛋白相关激酶A（TrkA），原肌球蛋白相关激酶B（TrkB），原肌球蛋白相关激酶C（TrkC）和/或c-FMS（集落刺激因子-1的细胞受体 （CSF-1））。
-
公开(公告)号：US20150274725A1
公开(公告)日：2015-10-01
申请号：US14741017
申请日：2015-06-16
申请人： Genzyme Corporation
发明人： John L. KANE, JR. , Gloria MATTHEWS , Markus METZ , Michael KOTHE , Jinyu LIU , Andrew SCHOLTE
IPC分类号： C07D471/04 , C07D403/04 , C07D471/10 , C07D401/14 , C07D413/14 , C07D405/14 , C07F9/50 , C07D401/04
CPC分类号： A61K31/551 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D519/00 , C07F9/5022 , C07F9/6506 , C07F9/65583 , C07F9/6561
摘要： Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
-
公开(公告)号：US20190183903A1
公开(公告)日：2019-06-20
申请号：US16194696
申请日：2018-11-19
申请人： Genzyme Corporation
发明人： John L. KANE, JR. , Gloria MATTHEWS , Markus METZ , Michael KOTHE , Jinyu LIU , Andrew SCHOLTE
IPC分类号： A61K31/551 , C07F9/6506 , C07D471/08 , C07D403/14 , C07D401/12 , C07D487/04 , C07D405/14 , C07D401/14 , C07D401/04 , C07D403/04 , A61K31/4725 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/4184 , C07F9/6561 , C07F9/6558 , C07D471/04 , C07D487/08 , C07D417/14 , C07D413/14 , C07F9/50 , C07D519/00 , C07D471/10 , C07D413/04 , C07D487/10
CPC分类号： A61K31/551 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D519/00 , C07F9/5022 , C07F9/6506 , C07F9/65583 , C07F9/6561
摘要： Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
-
公开(公告)号：US20240189322A1
公开(公告)日：2024-06-13
申请号：US18516091
申请日：2023-11-21
申请人： Genzyme Corporation
发明人： John L. KANE, JR. , Gloria MATTHEWS , Markus METZ , Michael KOTHE , Jinyu LIU , Andrew SCHOLTE
IPC分类号： A61K31/551 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D519/00 , C07F9/50 , C07F9/6506 , C07F9/6558 , C07F9/6561
CPC分类号： A61K31/551 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D519/00 , C07F9/5022 , C07F9/6506 , C07F9/65583 , C07F9/6561
摘要： Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
-
公开(公告)号：US20170224704A1
公开(公告)日：2017-08-10
申请号：US15436195
申请日：2017-02-17
申请人： Genzyme Corporation
发明人： John L. KANE, JR. , Gloria MATTHEWS , Markus METZ , Michael KOTHE , Jinyu LIU , Andrew SCHOLTE
IPC分类号： A61K31/551 , A61K31/506 , A61K31/4439 , A61K31/5377 , A61K31/4725 , A61K31/4545 , A61K31/444 , A61K31/496 , A61K31/437 , A61K31/4184 , A61K31/501
CPC分类号： A61K31/551 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D519/00 , C07F9/5022 , C07F9/6506 , C07F9/65583 , C07F9/6561
摘要： Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
-
公开(公告)号：US20150158847A1
公开(公告)日：2015-06-11
申请号：US14564773
申请日：2014-12-09
申请人： Genzyme Corporation
发明人： John L. KANE, JR. , Gloria MATTHEWS , Markus METZ , Michael KOTHE , Jinyu LIU , Andrew SCHOLTE
IPC分类号： C07D403/04
CPC分类号： A61K31/551 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D519/00 , C07F9/5022 , C07F9/6506 , C07F9/65583 , C07F9/6561
摘要： Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.02 秒)
